Milvexian added to antiplatelet therapy after acute coronary syndrome does not significantly reduce major adverse cardiovascular events in high-risk patients.
Atrial Fibrillation Management and Outcomes
Moving in medRxiv, New England Journal of Medicine and Nature Medicine.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 6
Add Atrial Fibrillation Management and Outcomes as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in Atrial Fibrillation Management and Outcomes
Newest first · last 60 days
Catheter-directed thrombolysis reduces the risk of death, recurrence, or cardiorespiratory collapse within 7 days in patients with intermediate-high-risk pulmonary embolism, with only minimal bleeding risks.
Potent P2Y12 inhibitors combined with DOACs increase bleeding risk without reducing ischemic events in atrial fibrillation and acute coronary syndrome patients.
- Open access
Add Atrial Fibrillation Management and Outcomes as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6183
- medRxiv1716
- PNAS472
- Sci Adv398
- JAMA274
- Environ Res230
- BMJ200
- Nat Commun171
- Environ Pollution165
- Nature161
- NEJM146
- Science141
- Lancet132
- Cell Rep130
- Curr Biol108
- J Exp Bot108
- mBio107
- Plant Cell Environ107
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3